Skip to main content

Melbourne, Australia 20 February 2017: Cell Therapies commitment to, and excellence in, bringing innovative cellular therapies into clinical practise has been recognised with an IMAPAC Asia-Pacific Bioprocessing Excellence Award. Managing Director and  CEO Dr Tim Oldham accepted the award for “Best Bioprocessing Excellence in Australia (CMO Category)” at an awards ceremony in Singapore on 15 February.
“It is an honour to receive this award on behalf of our talented and committed team” said Dr Oldham after the ceremony. “This award recognizes both the critical role that specialized manufacturing and supply chain capabilities will play in ensuring patient access to innovative cell and gene therapies that can transform health outcomes, and confirms Cell Therapies’ leadership in the field in Asia Pacific”.
About APAC Bioprocessing Excellence Awards 
APAC Bioprocessing Excellence Awards aim to recognize outstanding bioprocessing people, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost and superior quality. Featuring top bioprocessing and biomanufacturing experts in the industry, along with the latest advances in technologies and bets practices in manufacturing, Asia’s Bioprocessing Excellence Awards aim to recognize outstanding leaders and trend-setters of today, and inspire innovators of tomorrow.
About Cell Therapies Pty Ltd
Cell Therapies is a leading provider of cGMP contract manufacturing and deployment services for cell and gene therapy products in Asia Pacific. Cell Therapies is dedicated to enabling patient access to, and furthering the development of, these ground breaking therapies on behalf of clients from around the world. Building on more than 15 years’ experience and strategic partnerships with our owner, Peter MacCallum Cancer Centre in Melbourne Australia and PharmaBio Corp in Japan, we provide a complete process development and GMP product supply service from translational studies through to commercial supply and can serve as a single access point for Asian deployment of cellular therapies for our clients.